Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D016769 | Embolism and Thrombosis NIH | 0.50 |
D004617 | Embolism NIH | 0.25 |
D013927 | Thrombosis NIH | 0.19 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001907 | Thromboembolism HPO | 0.21 |
HP:0002090 | Pneumonia HPO | 0.05 |
Navigate: Correlations HPO
There is one clinical trial.
The primary objectives of this pilot study protocol are to assess safety and feasibility of using the geko™ device in COVID-19. Regarding safety to patients, we will measure the rate of adverse events, primarily local site irritation or discomfort. Feasibility will be measured on the basis of recruitment; ability to enroll sufficient number of patients meeting criteria. Protocol adherence will be observed as the ability to deliver the study intervention to the patients randomized to the treatment arm within the prescribed timeline and ability to complete the course of treatment. Additionally, we plan to measure patient outcomes such as ICU admission and death. The findings of this study have the potential to decrease the complications seen in COVID-19 infections.
Description: Feasibility will be measured on the basis of recruitment; ability to enroll sufficient number of patients meeting criteria
Measure: Feasibility of recruitment Time: Within a two year periodDescription: We will measure the rate of adverse events, primarily local site irritation or discomfort
Measure: Safety of device: AE Time: From ICU admission to discharge or death in ICU up to 28 days whichever comes first.Description: We will assess our ability to deliver the study intervention to the patients randomized to the treatment arm within the prescribed timeline and ability to complete the course of treatment
Measure: Protocol Adherence Time: From ICU admission to discharge or death in ICU up to 28 days whichever comes first.Description: The impact of the geko™ device on patient outcomes in critically ill COVID-19 patients.
Measure: Mortality Time: From date of admission to discharge from ICU or death in hospital assessed up to a 28 days whichever comes first.Description: The impact of the geko™ device on patient outcomes in critically ill COVID-19 patients.
Measure: Morbidity Time: From date of admission to discharge from ICU assessed up to a 28 days whichever comes first.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports